和肽素对急性冠脉综合征早期诊断和预后的附加价值
入院和肽素联合cTnI的敏感性和NPV均为100%,显著优于单用cTnI的57%和70%;联合AUC为0.975,高于单用cTnI的0.888。入院和肽素是多变量回归中MACE的独立预测因子(OR 0.01,95%CI 0.0-0.8,P=0.04),高和肽素组1年MACE和血运重建率最高。
要点
- 疑似NSTE-ACS且症状发作6小时内、无ST段抬高者,入院时联合检测和肽素+cTnI可将早期排除NSTEMI的敏感性和NPV均提至100%(单用cTnI为57%和70%)。
- 联合和肽素与cTnI的AUC为0.975(P<0.001),显著高于单用cTnI的AUC 0.888(P<0.001)。
- 入院和肽素在NSTEMI患者中显著高于UA患者,并与GRACE、TIMI、SYNTAX评分均呈正相关。
- 入院和肽素是多变量回归中MACE的独立预测因子(OR 0.01,95%CI 0.0-0.8,P=0.04);高和肽素者1年MACE及血运重建率最高。
- 联合检测有助于早期排除NSTEMI,且在高NPV方面几乎不依赖于胸痛发作时间(CPO),对3小时内就诊者亦有良好预后价值。
适用人群与场景
- 疑似ACS、典型缺血性胸痛发作6小时内、心电图无ST段抬高的患者(纳入标准)。
诊断标准与关键阈值
- 纳入标准:疑似ACS、典型缺血性胸痛发作6小时内、心电图无ST段抬高。
- 诊断分组:不稳定型心绞痛(UA)与NSTEMI。
- 风险评分:GRACE、TIMI、SYNTAX评分用于与和肽素的相关性分析。
- 终点:1年MACE包括心源性死亡、再梗死、缺血事件再住院、心力衰竭、卒中及靶病变血运重建(TLR)。
处置流程与药物剂量
- 第一步:对疑似NSTE-ACS且症状发作6小时内、无ST段抬高者,入院时采集静脉血同时检测和肽素与cTnI。
- 第三步:联合入院和肽素与cTnI用于早期排除NSTEMI(联合敏感性和NPV均为100%,单用cTnI为57%和70%)。
- 第四步:入院和肽素水平可用于风险分层和1年MACE预测(独立预测因子OR 0.01,95%CI 0.0-0.8,P=0.04)。
- 原文未提及和肽素的具体给药剂量、途径、频次或目标值(和肽素为检测生物标志物,非治疗药物)。
红旗征与不能漏的情况
- 原文未提及具体的红旗征或需要立刻处理的情况。
研究设计与关键结果
- 主要结果:入院和肽素联合cTnI的敏感性和NPV均为100%,单用cTnI为57%和70%;联合AUC 0.975(P<0.001),单用cTnI AUC 0.888(P<0.001)。
- 次要结果:NSTEMI组入院和肽素显著高于UA组;和肽素与GRACE、TIMI、SYNTAX评分均正相关;入院和肽素为MACE独立预测因子(OR 0.01,95%CI 0.0-0.8,P=0.04);高和肽素组1年MACE及血运重建率最高。
- 不良事件:原文未单独列出不良事件,仅报告MACE组分。
证据类型、等级与局限
- 证据类型:前瞻性观察性研究(原文未明确写RCT)。
- 证据等级或推荐强度:原文未提及。
对床旁实践的改变
- 对疑似NSTE-ACS且症状发作6小时内、无ST段抬高者,入院时联合检测和肽素+cTnI可提高早期排除NSTEMI的敏感性和NPV(100% vs 单用cTnI 57%和70%)。
- 入院和肽素水平可用于辅助风险分层和1年MACE预测,高和肽素者MACE及血运重建率最高。
- 联合检测的早期排除价值在高NPV方面几乎不依赖于胸痛发作时间(CPO),对3小时内就诊者亦有良好预后价值。
- 不适用人群:原文未提及排除人群;症状发作超过6小时者未纳入研究。
指南或共识出处
- 原文未提及指南或共识名称;研究发表于Am J Emerg Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: One promising biomarker that has received substantial interest for the evaluation of suspected acute coronary syndromes (ACS) is copeptin. Therefore, our goal was to assess the additive value of copeptin for early diagnosis and prognosis of Non-ST segment acute coronary syndromes (NSTE-ACS).
METHODS: The study included ninety patients with suspected ACS. Patients with typical ischemic chest pain within six hours of symptom onset and without ST-segment elevation on electrocardiograph (ECG) were included. In addition to cardiac troponin I (cTnI), copeptin was assayed from venous blood samples obtained on admission, followed by serial troponin measurements six and twelve hours later. One year follow-up was performed for any major adverse cardiac events (MACEs) including cardiac death, re-infarction, re- hospitalization for ischemic events, heart failure, stroke and target lesion revascularization (TLR).
RESULTS: Of seventy nine patients included in the final analysis, Forty (50.6%) were diagnosed as unstable angina (UA), while thirty nine (49.4%) had a non-ST elevation myocardial infarction (NSTEMI). Copeptin level on admission was significantly higher among NSTEMI patients than those with UA. With regard to the correlation analyses, copeptin was positively correlated with each of, Global Registry of Acute Coronary Events (GRACE), Thrombolysis In Myocardial Infarction (TIMI) and synergy between percutaneous coronary intervention with taxus and cardiac surgery (SYNTAX) scores. The sensitivity and negative predictive value (NPV) of the combination of admission copeptin and cTn-I were 100% and 100%, respectively, versus 57% and 70%, respectively, with admission of cTn-I alone. The area under curve (AUC) of the combination of copeptin and cTn-I was (0.975, p < 0.001) and was significantly higher than the AUC of cTn-I alone (0.888, p < 0.001). Admission copeptin was an independent predictor for MACEs by multiple regression analysis (OR: 0.01, 95% CI: 0.0-0.8, P = 0.04). High values of copeptin had the highest rate of MACEs and coronary revascularization during one year of follow up.
CONCLUSION: The combination of copeptin and conventional troponin I aids in early rule out of NSTEMI virtually independent of chest pain onset (CPO) with high NPV in patients presenting within three hours from chest pain onset with excellent prognostic value for risk stratification and prediction of MACEs.
参考来源
- Ahmed TAN, Johny JS, Abdel-Malek MY, et al. The additive value of copeptin for early diagnosis and prognosis of acute coronary syndromes. Am J Emerg Med. 2021. PMID: 34481261. doi:10.1016/j.ajem.2021.08.069
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。